Sitemap - 2026 - The M&A Hunter
M&A Hunter: Banking Watch List
BMEA (Biomea Fusion) - The Science Breakdown
Must Read: Why We're Moving Up the Ladder
Iovance Biotherapeutics (IOVA) -- Dual Score Review
Viking Therapeutics (VKTX) -- Dual Score Review
The Shell Game Never Changes. Only the Label Does.
CABA Update: FDA Pushes Back on Myositis Trial Design
M&A Hunter, Week Ahead Preview
Banking M&A Portfolio Review The Hedge. 27 Names + 2 ETFs. The Full Banking Thesis.
Over $10 Bio Portfolio Review, Part 3 of 3 The Deep Bench. 22 Names. Dual Scores. Entry Zones.
Over $10 Bio Portfolio Review, Part 2 of 3 The Deep Bench. 23 Names. Dual Scores. Entry Zones.
Over $10 Bio Portfolio Review, Part 1 of 3 The Top Shelf. 23 Names. Dual Scores. Entry Zones.
Under $10 Bio Portfolio, Tier 5
Under $10 Bio Portfolio, Tier 4
Under $10 Bio Portfolio, Tier 3
M&A Hunter Portfolio Update: Under $10 Deck, Tier 2
M&A Hunter Portfolio Update: Under $10 Deck, Tier 1
SpaceX IPO: The Biggest Listing in History Is Coming. Here's Who Gets Paid.
How to Spot a Reverse Split in 10 Seconds
10 Rules That Keep You in the Game
The Next Domino: 5 Biotech M&A Targets After Merck's $6.7B TERN Takeout
Roth MKM Conference 2026, Reviews
INSM . Insmed . $144 . The CEO Chuckle
CZR . Caesars Entertainment . M&A in Play
Quick Note on PDUFA Risk Management
ALLO . Allogene Therapeutics .
M&A Hunter - Week Ahead Preview March 23-28, 2026
RBC Capital Markets just dropped a biotech takeover target list and it's worth talking about.
ARQT (Arcutis Biotherapeutics) - $450M Derm Franchise Nobody's Talking About
RVPH (Reviva Pharmaceuticals) - Where It All Started
Spyre Therapeutics (SYRE). Enrollment done early. Readout pulled forward. This is how it starts.
M&A Hunter: Week Ahead Preview
IDYA (IDEAYA Biosciences) - $32.83 as of today's close, March 13
Big Update for Paid Subscribers
Miami Health Week 2026, Day 4: 10 Names, Two Halves, One Takeaway
PZZA Part 3: A Real Buyer Finally Shows Up
Miami Health Week 2026 - Day 2 Conference Reviews
Miami health week 2026, day 1 "Flooded basement 21 hour marathon
M&A Hunter -- Week Ahead Preview (March 9-14, 2026)
Miami Health Week Tier 1: Estimated Buyout Prices
TD Cowen 46th Annual Health Care Conference, Day 3 Recap
TD Cowen 46th, Day 2 Replay: CATX & ROIV
TD Cowen Healthcare Conference: Day 2 Review
Distressed Biotech Playbook: TBPH vs ESSA, Same Setup, Very Different Assets
TD COWEN 46TH ANNUAL HEALTHCARE CONFERENCE | DAY 1 REVIEW
TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
M&A Hunter Week Ahead Preview, March 2-6, 2026
Iran, Fear Selling, and Why Your M&A Targets Just Got Cheaper
Friday night News Top 20 Bios Top 10 Bank & Top 5 others
Oppenheimer 36th Annual Healthcare Conference - Day 2 Recap
M&A Hunter: Wednesday Deep Dive. Turn Therapeutics (TTRX).
M&A Hunter: Oppenheimer 36th Healthcare Conference. Day 1 Recap.
OPPENHEIMER 36th HEALTHCARE CONFERENCE -- DAY 1
Banks Are Getting the AI Panic Treatment. Here's Why That's Your Opportunity.
FDA Just Changed the Game Again
What a Partnership Deal Does to a Stock
Week Ahead: Oppenheimer 36th Healthcare Conference Preview
BANKING SLEEVE -- M&A Rankings
The GOSS Lesson: When Your Deep Dive Becomes a Post-Mortem
Week Ahead Preview -- February 22, 2026
Why Most Biotech Investors Get Blindsided by Trial Failures
WEEK IN REVIEW: THE FDA JUST CHANGED EVERYTHING
CAPR -- Capricor Therapeutics: The DMD Cardiomyopathy Play Nobody's Talking About
Week Ahead Preview -- February 15, 2026
Conference Season Is Here. You Want In?
Guggenheim Emerging Outlook 2026: Day 2 Recap
GUGGENHEIM BIOTECH SUMMIT 2026 -- FULL REVIEW
Biotech Conference Season Is Here.
14 of Our Names Under One Roof
Biotech Watchlist -- Full M&A Review
ETF CORE HOLDINGS (The Wealth Ladder Foundation)
PAID POST: Holdings Update -- $10+ Conviction Plays
FREE POST: Holdings Update -- Under $10 Plays
Bank Sleeve Watchlist Update - February 5, 2026
Banking M&A Sleeve: February 2026 Update
Friday Top 5 M&A Plays + Portfolio Recap
BCRX — BioCryst Pharmaceuticals
The Anatomy of a $100 Million Pump and Dump: How OST Scammed American Retail Investors
The $9 Stock That's Worth $5 Million
SECURITIES LENDING: YOUR BROKER IS USING YOUR SHARES AGAINST YOU
THE WEEK AHEAD Fed Decision, Mag 7 Earnings, Tariff Threats & How to Stop Buying at Highs
MRKR — Nature Medicine Just Validated the Thesis
ZURA Bio Deep Dive — M&A Analysis
SUNDAY NEWS — JANUARY 18, 2026
JPM 2026 — DAY 3 COMPLETE WRAP-UP
JPM Healthcare Conference 2026 — Day 2 Full Recap
JPM Week 2026: The Biotech Dealmaking Superbowl Kicks Off Monday
GLSI Deep Dive: The Breast Cancer Vaccine
American Greed Ended. Then the Next Episode Started.
The Reverse Split Escape Hatch Just Closed — What Micro-Cap Biotech Investors Need to Know